{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T10:32:58Z","timestamp":1788690778497,"version":"build-2803163510"},"reference-count":184,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T00:00:00Z","timestamp":1729728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T00:00:00Z","timestamp":1729728000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biotechnol"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s12033-024-01301-8","type":"journal-article","created":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T08:02:50Z","timestamp":1729756970000},"page":"3800-3822","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Nanotechnology and CRISPR\/Cas-Mediated Gene Therapy Strategies: Potential Role for Treating Genetic Disorders"],"prefix":"10.1007","volume":"67","author":[{"given":"Guneet","family":"Kaur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasnoor","family":"Arora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhinashi Singh","family":"Sodhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonu","family":"Bhatia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3765-6743","authenticated-orcid":false,"given":"Navneet","family":"Batra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,24]]},"reference":[{"key":"1301_CR1","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1590\/s1679-45082017rb4024","volume":"15","author":"GAR Gon\u00e7alves","year":"2017","unstructured":"Gon\u00e7alves, G. A. R., & Paiva, R. D. M. A. (2017). Gene therapy: Advances, challenges and perspectives. Einstein (Sao Paulo)., 15, 369\u2013375.","journal-title":"Einstein (Sao Paulo)."},{"key":"1301_CR2","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/0163-7258(85)90017-8","volume":"29","author":"MJ Cline","year":"1985","unstructured":"Cline, M. J. (1985). Perspectives for gene therapy: Inserting new genetic information into mammalian cells by physical techniques and viral vectors. Pharmacology & Therapeutics, 29, 69\u201392.","journal-title":"Pharmacology & Therapeutics"},{"key":"1301_CR3","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1089\/hum.1990.1.4-371","volume":"1","author":"WF Anderson","year":"1990","unstructured":"Anderson, W. F. (1990). September 14, 1990: The beginning. Human Gene Therapy, 1, 371\u2013372.","journal-title":"Human Gene Therapy"},{"key":"1301_CR4","first-page":"3","volume":"52","author":"PS Jaswal","year":"2010","unstructured":"Jaswal, P. S., & Jolly, S. (2010). Germ-line engineering and future generations: An ethical and legal outlook. Journal of Indian Law Institute, 52, 3\u201315.","journal-title":"Journal of Indian Law Institute"},{"key":"1301_CR5","volume-title":"Advanced biotechnology","author":"RC Dubey","year":"2014","unstructured":"Dubey, R. C. (2014). Advanced biotechnology. S. Chand Publishing."},{"key":"1301_CR6","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jgg.2023.08.001","volume":"51","author":"Y Zhang","year":"2023","unstructured":"Zhang, Y., & Wu, Z. Y. (2023). Gene therapy for monogenic disorders: Challenges, strategies, and perspectives. Journal of Genetics and Genomics, 51, 133\u2013143.","journal-title":"Journal of Genetics and Genomics"},{"key":"1301_CR7","doi-asserted-by":"publisher","first-page":"2986","DOI":"10.1016\/j.csbj.2022.06.015","volume":"20","author":"X Wu","year":"2022","unstructured":"Wu, X., He, X., Liu, F., Jiang, X., Wang, P., Zhang, J., & Jiang, J. (2022). Development and clinical translation of ex vivo gene therapy. Computational and Structural Biotechnology Journal, 20, 2986\u20133003.","journal-title":"Computational and Structural Biotechnology Journal"},{"key":"1301_CR8","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41392-021-00487-6","volume":"6","author":"JT Bulcha","year":"2021","unstructured":"Bulcha, J. T., Wang, Y., Ma, H., Tai, P. W., & Gao, G. (2021). Viral vector platforms within the gene therapy landscape. Signal Transduction and Targeted Therapy, 6, 53.","journal-title":"Signal Transduction and Targeted Therapy"},{"key":"1301_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fgeed.2021.618346","volume":"3","author":"E Papanikolaou","year":"2021","unstructured":"Papanikolaou, E., & Bosio, A. (2021). The promise and the hope of gene therapy. Frontiers in Genomic Editing, 3, 618346.","journal-title":"Frontiers in Genomic Editing"},{"key":"1301_CR10","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/gt.2017.77","volume":"24","author":"F Carrasco-Ramiro","year":"2017","unstructured":"Carrasco-Ramiro, F., Peir\u00f3-Pastor, R., & Aguado, B. (2017). Human genomics projects and precision medicine. Gene Therapy, 24, 551\u2013561.","journal-title":"Gene Therapy"},{"key":"1301_CR11","unstructured":"Mahoney, A., Nassif, N., O'Brien, B., Simpson, A. (2022). Viral vectors in gene therapy and clinical applications, in molecular cloning (Dincer, S., Aysun Mercimek Takci, H., and Sumengen Ozdenef, M eds), IntechOpen"},{"key":"1301_CR12","doi-asserted-by":"publisher","first-page":"856","DOI":"10.3390\/pharmaceutics15030856","volume":"15","author":"H Hosseinkhani","year":"2023","unstructured":"Hosseinkhani, H., Domb, A. J., Sharifzadeh, G., & Nahum, V. (2023). Gene therapy for regenerative medicine. Pharmaceutics, 15, 856.","journal-title":"Pharmaceutics"},{"key":"1301_CR13","volume-title":"Retroviruses","year":"1997","unstructured":"Coffin, J. M., Hughes, S. H., & Varmus, H. E. (Eds.). (1997). Retroviruses. Cold Spring Harbor Laboratory Press."},{"key":"1301_CR14","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1128\/mr.57.3.511-521.1993","volume":"57","author":"RV Guntaka","year":"1993","unstructured":"Guntaka, R. V. (1993). Transcription termination and polyadenylation in retroviruses. Microbiology Review, 57, 511\u2013521.","journal-title":"Microbiology Review"},{"key":"1301_CR15","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/nrmicro1579","volume":"5","author":"Y Suzuki","year":"2007","unstructured":"Suzuki, Y., & Craigie, R. (2007). The road to chromatin\u2014nuclear entry of retroviruses. Nature Reviews Microbiology, 5, 187\u2013196.","journal-title":"Nature Reviews Microbiology"},{"key":"1301_CR16","first-page":"211","volume-title":"Pediatric Allergy: Principles and Practice","author":"M Catherine","year":"2010","unstructured":"Catherine, M., Bollard, C. R., Cruz, Y., & Brenner, M. K. (2010). Gene Therapy and Allergy. In D. Y. M. Leung, H. A. Sampson, R. Geha, & S. J. Szefler (Eds.), Pediatric Allergy: Principles and Practice (2nd ed., pp. 211\u2013222). Saunders.","edition":"2"},{"key":"1301_CR17","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.ymthe.2004.07.013","volume":"10","author":"N Tatsis","year":"2004","unstructured":"Tatsis, N., & Ertl, H. C. (2004). Adenoviruses as vaccine vectors. Molecular Therapy, 10, 616\u2013629.","journal-title":"Molecular Therapy"},{"key":"1301_CR18","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1634\/theoncologist.7-1-46","volume":"7","author":"SA Vorburger","year":"2002","unstructured":"Vorburger, S. A., & Hunt, K. K. (2002). Adenoviral gene therapy. The Oncologist, 7, 46\u201359.","journal-title":"The Oncologist"},{"key":"1301_CR19","doi-asserted-by":"publisher","first-page":"4297","DOI":"10.1158\/0008-5472.CAN-09-3567","volume":"70","author":"V Cerullo","year":"2010","unstructured":"Cerullo, V., Pesonen, S., Diaconu, I., Escutenaire, S., Arstila, P. T., Ugolini, M., Nokisalmi, P., Raki, M., Laasonen, L., S\u00e4rkioja, M., & Rajecki, M. (2010). Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients. Cancer Research, 70, 4297\u20134309.","journal-title":"Cancer Research"},{"key":"1301_CR20","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.molmed.2012.04.008","volume":"18","author":"JK Kaufmann","year":"2012","unstructured":"Kaufmann, J. K., & Nettelbeck, D. M. (2012). Virus chimeras for gene therapy, vaccination, and oncolysis: Adenoviruses and beyond. Trends in Molecular Medicine, 18, 365\u2013376.","journal-title":"Trends in Molecular Medicine"},{"key":"1301_CR21","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1089\/hum.2013.2527","volume":"25","author":"RG Crystal","year":"2014","unstructured":"Crystal, R. G. (2014). Adenovirus: The first effective in vivo gene delivery vector. Human Gene Therapy, 25, 3\u201311.","journal-title":"Human Gene Therapy"},{"key":"1301_CR22","doi-asserted-by":"publisher","first-page":"86","DOI":"10.2174\/1566523214666140302193709","volume":"14","author":"B Balakrishnan","year":"2014","unstructured":"Balakrishnan, B., Jayandharan, G. R. (2014). Basic biology of adeno-associated virus (AAV) vectors used in gene therapy. Current Gene Therapy, 14, 86\u2013100.","journal-title":"Current Gene Therapy"},{"key":"1301_CR23","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s40259-017-0234-5","volume":"31","author":"MF Naso","year":"2017","unstructured":"Naso, M. F., Tomkowicz, B., Perry, W. L., III., & Strohl, W. R. (2017). Adeno-associated virus (AAV) as a vector for gene therapy. BioDrugs, 31, 317\u2013334.","journal-title":"BioDrugs"},{"key":"1301_CR24","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jconrel.2012.04.008","volume":"161","author":"M Giacca","year":"2012","unstructured":"Giacca, M., & Zacchigna, S. (2012). Virus-mediated gene delivery for human gene therapy. Journal of Controlled Release, 161, 377\u2013388.","journal-title":"Journal of Controlled Release"},{"key":"1301_CR25","first-page":"603","volume-title":"Methods in enzymology","author":"K Franz","year":"2011","unstructured":"Franz, K., Singh, A., & Weinberger, L. S. (2011). Lentiviral vectors to study stochastic noise in gene expression. In J. Bridewell-Rabb (Ed.), Methods in enzymology (Vol. 497, pp. 603\u2013622). Academic press."},{"key":"1301_CR26","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1038\/s41375-018-0106-0","volume":"32","author":"MC Milone","year":"2018","unstructured":"Milone, M. C., & O\u2019Doherty, U. (2018). Clinical use of lentiviral vectors. Leukemia, 32, 1529\u20131541.","journal-title":"Leukemia"},{"key":"1301_CR27","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1038\/nbt0997-871","volume":"15","author":"R Zufferey","year":"1997","unstructured":"Zufferey, R., Nagy, D., Mandel, R. J., Naldini, L., & Trono, D. (1997). Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nature Biotechnology, 15, 871\u2013875.","journal-title":"Nature Biotechnology"},{"key":"1301_CR28","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.3390\/v13081526","volume":"13","author":"V Poletti","year":"2021","unstructured":"Poletti, V., & Mavilio, F. (2021). Designing lentiviral vectors for gene therapy of genetic diseases. Viruses, 13, 1526.","journal-title":"Viruses"},{"key":"1301_CR29","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3390\/diseases6020042","volume":"6","author":"K Lundstrom","year":"2018","unstructured":"Lundstrom, K. (2018). Viral vectors in gene therapy. Diseases, 6, 42.","journal-title":"Diseases"},{"key":"1301_CR30","doi-asserted-by":"publisher","first-page":"698","DOI":"10.3390\/v15030698","volume":"15","author":"K Lundstrom","year":"2023","unstructured":"Lundstrom, K. (2023). Viral vectors in gene therapy: Where do we stand in 2023? Viruses, 15, 698.","journal-title":"Viruses"},{"key":"1301_CR31","doi-asserted-by":"publisher","DOI":"10.1002\/btm2.10258","volume":"7","author":"Z Zhao","year":"2022","unstructured":"Zhao, Z., Anselmo, A. C., & Mitragotri, S. (2022). Viral vector-based gene therapies in the clinic. Bioengineering Translational Medicine, 7, e10258.","journal-title":"Bioengineering Translational Medicine"},{"key":"1301_CR32","first-page":"1","volume":"36","author":"L Vannucci","year":"2013","unstructured":"Vannucci, L., Lai, M., Chiuppesi, F., Ceccherini-Nelli, L., & Pistello, M. (2013). Viral vectors: A look back and ahead on gene transfer technology. New Microbiologica, 36, 1\u201322.","journal-title":"New Microbiologica"},{"key":"1301_CR33","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1146\/annurev-virology-101416-041936","volume":"4","author":"F Mingozzi","year":"2017","unstructured":"Mingozzi, F., & High, K. A. (2017). Overcoming the host immune response to adeno-associated virus gene delivery vectors: The race between clearance, tolerance, neutralization, and escape. Annual Review of Virology, 4, 511\u2013534.","journal-title":"Annual Review of Virology"},{"key":"1301_CR34","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.virol.2005.09.012","volume":"344","author":"M Yamashita","year":"2006","unstructured":"Yamashita, M., & Emerman, M. (2006). Retroviral infection of non-dividing cells: Old and new perspectives. Virology, 344, 88\u201393.","journal-title":"Virology"},{"key":"1301_CR35","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1021\/cb100285n","volume":"6","author":"JH Urban","year":"2011","unstructured":"Urban, J. H., & Merten, C. A. (2011). Retroviral display in gene therapy, protein engineering, and vaccine development. ACS Chemical Biology, 6, 61\u201374.","journal-title":"ACS Chemical Biology"},{"key":"1301_CR36","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.gendis.2017.04.001","volume":"4","author":"CS Lee","year":"2017","unstructured":"Lee, C. S., Bishop, E. S., Zhang, R., Yu, X., Farina, E. M., Yan, S., Zhao, C., Zeng, Z., Shu, Y., Wu, X., & Lei, J. (2017). Adenovirus-mediated gene delivery: Potential applications for gene and cell-based therapies in the new era of personalized medicine. Genes Diseases, 4, 43\u201363.","journal-title":"Genes Diseases"},{"key":"1301_CR37","unstructured":"Gasc\u00f3n, A.R., del Pozo-Rodr\u00edguez, A. and Solin\u00eds, M.\u00c1. (2013). Non-viral delivery systems in gene therapy, in\u00a0Gene therapy-tools and potential applications (Martin, F. ed), IntechOpen."},{"key":"1301_CR38","doi-asserted-by":"crossref","unstructured":"Ramamoorth, M. and Narvekar, A. (2015). Non-viral vectors in gene therapy-an overview.\u00a0Journal of Clinical and Diagnostic Research, 9, GE01\u2013GE06.","DOI":"10.7860\/JCDR\/2015\/10443.5394"},{"key":"1301_CR39","first-page":"78","volume":"23","author":"H Zu","year":"2021","unstructured":"Zu, H., & Gao, D. (2021). Non-viral vectors in gene therapy: Recent development, challenges, and prospects. American Association of Pharmaceutical Scientists Journal, 23, 78.","journal-title":"American Association of Pharmaceutical Scientists Journal"},{"key":"1301_CR40","doi-asserted-by":"crossref","unstructured":"Hobson, D.W. (2016) The commercialization of medical nanotechnology for medical applications.\u00a0In Prokop, A., and Weissig, V. (eds)  Intracellular Delivery III: Market Entry Barriers of Nanomedicines. Springer, pp. 405\u2013449.","DOI":"10.1007\/978-3-319-43525-1_17"},{"key":"1301_CR41","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1111\/joim.13254","volume":"290","author":"S Sindhwani","year":"2021","unstructured":"Sindhwani, S., & Chan, W. C. (2021). Nanotechnology for modern medicine: Next step towards clinical translation. Journal of Internal Medicine, 290, 486\u2013498.","journal-title":"Journal of Internal Medicine"},{"key":"1301_CR42","doi-asserted-by":"crossref","unstructured":"Laouini, S. E., Bouafia, A., Soldatov, A. V., Algarni, H., Tedjani, M. L., Ali, G. A., & Barhoum, A. (2021). Green synthesized of Ag\/Ag2O nanoparticles using aqueous leaves extracts of Phoenix dactylifera L. and their azo dye photodegradation. Membranes, 11, 468.","DOI":"10.3390\/membranes11070468"},{"key":"1301_CR43","first-page":"9","volume":"1","author":"KI Bogutska","year":"2013","unstructured":"Bogutska, K. I., Sklyarov, Y. P., & Prylutskyy, Y. (2013). Zinc and zinc nanoparticles: Biological role and application in biomedicine. Ukrainica Bioorganica Acta, 1, 9\u201316.","journal-title":"Ukrainica Bioorganica Acta"},{"key":"1301_CR44","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.reffit.2017.03.002","volume":"3","author":"H Agarwal","year":"2017","unstructured":"Agarwal, H., Kumar, S. V., & Rajeshkumar, S. (2017). A review on green synthesis of zinc oxide nanoparticles\u2014An eco-friendly approach. Resource-Efficient Technologies, 3, 406\u2013413.","journal-title":"Resource-Efficient Technologies"},{"key":"1301_CR45","doi-asserted-by":"publisher","first-page":"081","DOI":"10.4172\/2161-0444.1000247","volume":"5","author":"AP Nikalje","year":"2015","unstructured":"Nikalje, A. P. (2015). Nanotechnology and its applications in medicine. Medicinal Chemistry, 5, 081\u2013089.","journal-title":"Medicinal Chemistry"},{"key":"1301_CR46","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1515\/ntrev-2013-0013","volume":"3","author":"WH Gmeiner","year":"2014","unstructured":"Gmeiner, W. H., & Ghosh, S. (2014). Nanotechnology for cancer treatment. Nanotechnology Reviews, 3, 111\u2013122.","journal-title":"Nanotechnology Reviews"},{"key":"1301_CR47","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1039\/C9BM01643K","volume":"8","author":"Q Muhammad","year":"2020","unstructured":"Muhammad, Q., Jang, Y., Kang, S. H., Moon, J., Kim, W. J., & Park, H. (2020). Modulation of immune responses with nanoparticles and reduction of their immunotoxicity. Biomaterials Science, 8, 1490\u20131501.","journal-title":"Biomaterials Science"},{"key":"1301_CR48","doi-asserted-by":"publisher","first-page":"94","DOI":"10.3390\/nano7050094","volume":"7","author":"MK Riley","year":"2017","unstructured":"Riley, M. K., & Vermerris, W. (2017). Recent advances in nanomaterials for gene delivery\u2014a review. Nanomaterial, 7, 94.","journal-title":"Nanomaterial"},{"key":"1301_CR49","doi-asserted-by":"crossref","unstructured":"Xin, Y., Huang, M., Guo, W.W., Huang, Q., Zhang, L.Z., Jiang, G. (2017) Nano-based delivery of RNAi in cancer therapy.\u00a0Molecular Cancer,\u00a016.","DOI":"10.1186\/s12943-017-0683-y"},{"key":"1301_CR50","doi-asserted-by":"publisher","first-page":"5491","DOI":"10.3390\/ijms20215491","volume":"20","author":"S Patil","year":"2019","unstructured":"Patil, S., Gao, Y. G., Lin, X., Li, Y., Dang, K., Tian, Y., Zhang, W. J., Jiang, S. F., Qadir, A., & Qian, A. R. (2019). The development of functional non-viral vectors for gene delivery. International Journal of Molecular Sciences, 20, 5491.","journal-title":"International Journal of Molecular Sciences"},{"key":"1301_CR51","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.jsps.2017.10.012","volume":"26","author":"SA Rizvi","year":"2018","unstructured":"Rizvi, S. A., & Saleh, A. M. (2018). Applications of nanoparticle systems in drug delivery technology. Saudi Pharmaceutical Journal, 26, 64\u201370.","journal-title":"Saudi Pharmaceutical Journal"},{"key":"1301_CR52","doi-asserted-by":"publisher","first-page":"472","DOI":"10.7897\/2277-4343.04334","volume":"4","author":"AN Sahu","year":"2013","unstructured":"Sahu, A. N. (2013). Nanotechnology in herbal medicines and cosmetics. International Journal of Research in Ayurveda Pharmacy, 4, 472\u2013474.","journal-title":"International Journal of Research in Ayurveda Pharmacy"},{"key":"1301_CR53","doi-asserted-by":"publisher","first-page":"707","DOI":"10.3390\/ph14080707","volume":"14","author":"S Anjum","year":"2021","unstructured":"Anjum, S., Ishaque, S., Fatima, H., Farooq, W., Hano, C., Abbasi, B. H., & Anjum, I. (2021). Emerging applications of nanotechnology in healthcare systems: Grand challenges and perspectives. Pharmaceuticals, 14, 707.","journal-title":"Pharmaceuticals"},{"key":"1301_CR54","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1515\/gps-2020-0031","volume":"9","author":"AME Shafey","year":"2020","unstructured":"Shafey, A. M. E. (2020). Green synthesis of metal and metal oxide nanoparticles from plant leaf extracts and their applications: A review. Green Processing and Synthesis, 9, 304\u2013339.","journal-title":"Green Processing and Synthesis"},{"key":"1301_CR55","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.01264","volume":"10","author":"VS Madamsetty","year":"2019","unstructured":"Madamsetty, V. S., Mukherjee, A., & Mukherjee, S. (2019). Recent trends of the bio-inspired nanoparticles in cancer theranostics. Frontiers in Pharmacology, 10, 488377.","journal-title":"Frontiers in Pharmacology"},{"key":"1301_CR56","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s11671-021-03628-6","volume":"16","author":"S Gavas","year":"2021","unstructured":"Gavas, S., Quazi, S., & Karpi\u0144ski, T. M. (2021). Nanoparticles for cancer therapy: Current progress and challenges. Nanoscale Research Letters, 16, 173.","journal-title":"Nanoscale Research Letters"},{"key":"1301_CR57","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/417305","volume":"2014","author":"JK Patra","year":"2014","unstructured":"Patra, J. K., & Baek, K. H. (2014). Green nanobiotechnology: Factors affecting synthesis and characterization techniques. Journal of Nanomaterials, 2014, 417305.","journal-title":"Journal of Nanomaterials"},{"key":"1301_CR58","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3389\/fonc.2019.00297","volume":"9","author":"R Goswami","year":"2019","unstructured":"Goswami, R., Subramanian, G., Silayeva, L., Newkirk, I., Doctor, D., Chawla, K., Chattopadhyay, S., Chandra, D., Chilukuri, N., & Betapudi, V. (2019). Gene therapy leaves a vicious cycle. Frontiers in Oncology, 9, 297.","journal-title":"Frontiers in Oncology"},{"key":"1301_CR59","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1073\/pnas.97.2.811","volume":"97","author":"M Singh","year":"2000","unstructured":"Singh, M., Briones, M., Ott, G., & O\u2019Hagan, D. (2000). Cationic microparticles: A potent delivery system for DNA vaccines. Proceedings of National Academy Science, 97, 811\u2013816.","journal-title":"Proceedings of National Academy Science"},{"key":"1301_CR60","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.biopha.2006.07.093","volume":"60","author":"N Toub","year":"2006","unstructured":"Toub, N., Malvy, C., Fattal, E., & Couvreur, P. (2006). Innovative nanotechnologies for the delivery of oligonucleotides and siRNA. Biomedicine & Pharmacotherapy, 60, 607\u2013620.","journal-title":"Biomedicine & Pharmacotherapy"},{"key":"1301_CR61","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1073\/pnas.98.3.1200","volume":"98","author":"D Putnam","year":"2001","unstructured":"Putnam, D., Gentry, C. A., Pack, D. W., & Langer, R. (2001). Polymer-based gene delivery with low cytotoxicity by a unique balance of side-chain termini. Proceedings of National Academy Science, 98, 1200\u20131205.","journal-title":"Proceedings of National Academy Science"},{"key":"1301_CR62","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1002\/med.20003","volume":"24","author":"W Tan","year":"2004","unstructured":"Tan, W., Wang, K., He, X., Zhao, X. J., Drake, T., Wang, L., & Bagwe, R. P. (2004). Bionanotechnology based on silica nanoparticles. Medicinal Research Reviews, 24, 621\u2013638.","journal-title":"Medicinal Research Reviews"},{"key":"1301_CR63","doi-asserted-by":"publisher","first-page":"149","DOI":"10.3109\/08982109509039915","volume":"5","author":"R Reszka","year":"1995","unstructured":"Reszka, R., Zhu, J. H., Weber, F., Walther, W., Greferath, R., & Dyballa, S. (1995). Liposome mediated transfer of marker and cytokine genes into rat and human glioblastoma cells in vitro and in vivo. Journal of Liposome Research, 5, 149\u2013167.","journal-title":"Journal of Liposome Research"},{"key":"1301_CR64","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/28.10.e45","volume":"28","author":"M Junghans","year":"2000","unstructured":"Junghans, M., Kreuter, J., & Zimmer, A. (2000). Antisense delivery using protamine\u2013oligonucleotide particles. Nucleic Acids Research, 28, e45.","journal-title":"Nucleic Acids Research"},{"key":"1301_CR65","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1007\/s11095-005-4590-3","volume":"22","author":"G Kaul","year":"2005","unstructured":"Kaul, G., & Amiji, M. (2005). Tumor-targeted gene delivery using poly (ethylene glycol)-modified gelatin nanoparticles: In vitro and in vivo studies. Pharmaceutical Research, 22, 951\u2013961.","journal-title":"Pharmaceutical Research"},{"key":"1301_CR66","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1097\/NEN.0b013e318225038c","volume":"70","author":"JF Poduslo","year":"2011","unstructured":"Poduslo, J. F., Hultman, K. L., Curran, G. L., Preboske, G. M., Chamberlain, R., Marja\u0144ska, M., Garwood, M., Jack, C. R., Jr., & Wengenack, T. M. (2011). Targeting vascular amyloid in arterioles of Alzheimer disease transgenic mice with amyloid \u03b2 protein antibody-coated nanoparticles. Journal of Neuropathology and Experimental Neurology, 70, 653\u2013661.","journal-title":"Journal of Neuropathology and Experimental Neurology"},{"key":"1301_CR67","doi-asserted-by":"publisher","first-page":"12833","DOI":"10.1021\/acsomega.9b01411","volume":"4","author":"SK Sonawane","year":"2019","unstructured":"Sonawane, S. K., Ahmad, A., & Chinnathambi, S. (2019). Protein-capped metal nanoparticles inhibit tau aggregation in Alzheimer\u2019s disease. ACS Omega, 4, 12833\u201312840.","journal-title":"ACS Omega"},{"key":"1301_CR68","first-page":"1","volume":"16","author":"E S\u00e1nchez-L\u00f3pez","year":"2018","unstructured":"S\u00e1nchez-L\u00f3pez, E., Ettcheto, M., Egea, M. A., Espina, M., Cano, A., Calpena, A. C., Camins, A., Carmona, N., Silva, A. M., Souto, E. B., & Garc\u00eda, M. L. (2018). Memantine loaded PLGA PEGylated nanoparticles for Alzheimer\u2019s disease: In vitro and in vivo characterization. Journal of Nanbiotechnology, 16, 1\u201316.","journal-title":"Journal of Nanbiotechnology"},{"key":"1301_CR69","doi-asserted-by":"publisher","first-page":"3631","DOI":"10.1002\/smll.201201068","volume":"8","author":"YH Liao","year":"2012","unstructured":"Liao, Y. H., Chang, Y. J., Yoshiike, Y., Chang, Y. C., & Chen, Y. R. (2012). Negatively charged gold nanoparticles inhibit Alzheimer\u2019s amyloid-\u03b2 fibrillization, induce fibril dissociation, and mitigate neurotoxicity. Small (Weinheim an der Bergstrasse, Germany), 8, 3631\u20133639.","journal-title":"Small (Weinheim an der Bergstrasse, Germany)"},{"key":"1301_CR70","doi-asserted-by":"publisher","first-page":"5892","DOI":"10.1074\/jbc.M404751200","volume":"280","author":"F Yang","year":"2005","unstructured":"Yang, F., Lim, G. P., Begum, A. N., Ubeda, O. J., Simmons, M. R., Ambegaokar, S. S., Chen, P. P., Kayed, R., Glabe, C. G., Frautschy, S. A., & Cole, G. M. (2005). Curcumin inhibits formation of amyloid \u03b2 oligomers and fibrils, binds plaques, and reduces amyloid in vivo. Journal of Biological Chemistry, 280, 5892\u20135901.","journal-title":"Journal of Biological Chemistry"},{"key":"1301_CR71","doi-asserted-by":"publisher","first-page":"131","DOI":"10.2174\/1567205053585882","volume":"2","author":"JM Ringman","year":"2005","unstructured":"Ringman, J. M., Frautschy, S. A., Cole, G. M., Masterman, D. L., & Cummings, J. L. (2005). A potential role of the curry spice curcumin in Alzheimer\u2019s disease. Current Alzheimer Research, 2, 131\u2013136.","journal-title":"Current Alzheimer Research"},{"key":"1301_CR72","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.bcp.2007.08.016","volume":"75","author":"A Goel","year":"2008","unstructured":"Goel, A., Kunnumakkara, A. B., & Aggarwal, B. B. (2008). Curcumin as \u201cCurecumin\u201d: From kitchen to clinic. Biochemical Pharmacology, 75, 787\u2013809.","journal-title":"Biochemical Pharmacology"},{"key":"1301_CR73","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0032616","volume":"7","author":"A Mathew","year":"2012","unstructured":"Mathew, A., Fukuda, T., Nagaoka, Y., Hasumura, T., Morimoto, H., Yoshida, Y., Maekawa, T., Venugopal, K., & Kumar, D. S. (2012). Curcumin loaded-PLGA nanoparticles conjugated with Tet-1 peptide for potential use in Alzheimer\u2019s disease. PLoS ONE, 7, e32616.","journal-title":"PLoS ONE"},{"key":"1301_CR74","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.jconrel.2007.12.018","volume":"127","author":"IP Kaur","year":"2008","unstructured":"Kaur, I. P., Bhandari, R., Bhandari, S., & Kakkar, V. (2008). Potential of solid lipid nanoparticles in brain targeting. Journal of Controlled Release, 127, 97\u2013109.","journal-title":"Journal of Controlled Release"},{"key":"1301_CR75","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1021\/acschemneuro.6b00207","volume":"7","author":"P Kundu","year":"2016","unstructured":"Kundu, P., Das, M., Tripathy, K., & Sahoo, S. K. (2016). Delivery of dual drug loaded lipid based nanoparticles across the blood\u2013brain barrier impart enhanced neuroprotection in a rotenone induced mouse model of Parkinson\u2019s disease. ACS Chemical Neuroscience, 7, 1658\u20131670.","journal-title":"ACS Chemical Neuroscience"},{"key":"1301_CR76","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1002\/psc.324","volume":"7","author":"AB Clippingdale","year":"2001","unstructured":"Clippingdale, A. B., Wade, J. D., & Barrow, C. J. (2001). The amyloid-\u03b2 peptide and its role in Alzheimer\u2019s disease. Journal of Peptide Science, 7, 227\u2013249.","journal-title":"Journal of Peptide Science"},{"key":"1301_CR77","doi-asserted-by":"publisher","first-page":"6547","DOI":"10.2147\/IJN.S120939","volume":"11","author":"C Bi","year":"2016","unstructured":"Bi, C., Wang, A., Chu, Y., Liu, S., Mu, H., Liu, W., Wu, Z., Sun, K., & Li, Y. (2016). Intranasal delivery of rotigotine to the brain with lactoferrin-modified PEG-PLGA nanoparticles for Parkinson\u2019s disease treatment. International Journal of Nanomedicine, 11, 6547\u20136559.","journal-title":"International Journal of Nanomedicine"},{"key":"1301_CR78","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.pharep.2014.09.004","volume":"67","author":"A Kumar","year":"2015","unstructured":"Kumar, A., & Singh, A. (2015). A review on Alzheimer\u2019s disease pathophysiology and its management: An update. Pharmacological Reports, 67, 195\u2013203.","journal-title":"Pharmacological Reports"},{"key":"1301_CR79","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13024-019-0333-5","volume":"14","author":"MA DeTure","year":"2019","unstructured":"DeTure, M. A., & Dickson, D. W. (2019). The neuropathological diagnosis of Alzheimer\u2019s disease. Molecular Neurodegeneration, 14, 32.","journal-title":"Molecular Neurodegeneration"},{"key":"1301_CR80","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1177\/0891988710383572","volume":"23","author":"LM Bekris","year":"2010","unstructured":"Bekris, L. M., Mata, I. F., & Zabetian, C. P. (2010). The genetics of Parkinson disease. Journal of Geriatric Psychiatry and Neurology, 23, 228\u2013242.","journal-title":"Journal of Geriatric Psychiatry and Neurology"},{"key":"1301_CR81","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/S1474-4422(11)70213-7","volume":"10","author":"K Vekrellis","year":"2011","unstructured":"Vekrellis, K., Xilouri, M., Emmanouilidou, E., Rideout, H. J., & Stefanis, L. (2011). Pathological roles of \u03b1-synuclein in neurological disorders. Lancet Neurology, 10, 1015\u20131025.","journal-title":"Lancet Neurology"},{"key":"1301_CR82","doi-asserted-by":"crossref","unstructured":"Desplats, P., Patel, P., Kosberg, K., Mante, M., Patrick, C., Rockenstein, E., Fujita, M., Hashimoto, M., Masliah, E. (2012). Combined exposure to Maneb and Paraquat alters transcriptional regulation of neurogenesis-related genes in mice models of Parkinson\u2019s disease.\u00a0Molecular Neurodegeneration,\u00a07.","DOI":"10.1186\/1750-1326-7-49"},{"key":"1301_CR83","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1007\/s12035-012-8369-3","volume":"47","author":"M Ozansoy","year":"2013","unstructured":"Ozansoy, M., & Ba\u015fak, A. N. (2013). The central theme of Parkinson\u2019s disease: \u03b1-synuclein. Molecular Neurobiology, 47, 460\u2013465.","journal-title":"Molecular Neurobiology"},{"key":"1301_CR84","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1016\/j.nano.2016.06.009","volume":"12","author":"W DeCoteau","year":"2016","unstructured":"DeCoteau, W., Heckman, K. L., Estevez, A. Y., Reed, K. J., Costanzo, W., Sandford, D., Studlack, P., Clauss, J., Nichols, E., Lipps, J., & Parker, M. (2016). Cerium oxide nanoparticles with antioxidant properties ameliorate strength and prolong life in mouse model of amyotrophic lateral sclerosis. Nanomedicine Nanotechnology Biologie et M\u00e9decine, 12, 2311\u20132320.","journal-title":"Nanomedicine Nanotechnology Biologie et M\u00e9decine"},{"key":"1301_CR85","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1139\/jpn.0603","volume":"31","author":"A Montoya","year":"2006","unstructured":"Montoya, A., Price, B. H., Menear, M., & Lepage, M. (2006). Brain imaging and cognitive dysfunctions in Huntington\u2019s disease. Journal of Psychiatry and Neuroscience, 31, 21\u201329.","journal-title":"Journal of Psychiatry and Neuroscience"},{"key":"1301_CR86","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/nature05292","volume":"443","author":"MT Lin","year":"2006","unstructured":"Lin, M. T., & Beal, M. F. (2006). Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature, 443, 787\u2013795.","journal-title":"Nature"},{"key":"1301_CR87","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.ejpb.2017.04.032","volume":"117","author":"NG T\u00fcreli","year":"2017","unstructured":"T\u00fcreli, N. G., Torge, A., Juntke, J., Schwarz, B. C., Schneider-Daum, N., T\u00fcreli, A. E., Lehr, C. M., & Schneider, M. (2017). Ciprofloxacin-loaded PLGA nanoparticles against cystic fibrosis P. aeruginosa lung infections. European Journal of Pharmaceutics and Biopharmaceutics, 117, 363\u2013371.","journal-title":"European Journal of Pharmaceutics and Biopharmaceutics"},{"key":"1301_CR88","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1016\/j.ymthe.2018.05.014","volume":"26","author":"E Robinson","year":"2018","unstructured":"Robinson, E., MacDonald, K. D., Slaughter, K., McKinney, M., Patel, S., Sun, C., & Sahay, G. (2018). Lipid nanoparticle-delivered chemically modified mRNA restores chloride secretion in cystic fibrosis. Molecular Therapy, 26, 2034\u20132046.","journal-title":"Molecular Therapy"},{"key":"1301_CR89","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1164\/rccm.200505-840OE","volume":"173","author":"PB Davis","year":"2006","unstructured":"Davis, P. B. (2006). Cystic fibrosis since 1938. American Journal of Respiratory and Critical Care Medicine, 173, 475\u2013482.","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"1301_CR90","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1201\/9780429399039-17","volume-title":"Nano-Enabled Medical Applications","author":"J Chen","year":"2020","unstructured":"Chen, J., Patil, S., Seal, S., & McGinnis, J. F. (2020). Rare earth nanoparticles prevent retinal degeneration induced by intracellular peroxides. In L. P. Balogh (Ed.), Nano-Enabled Medical Applications (pp. 525\u2013546). Publishing."},{"key":"1301_CR91","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jconrel.2013.11.001","volume":"174","author":"S Papa","year":"2014","unstructured":"Papa, S., Ferrari, R., De Paola, M., Rossi, F., Mariani, A., Caron, I., Sammali, E., Peviani, M., Dell\u2019Oro, V., Colombo, C., & Morbidelli, M. (2014). Polymeric nanoparticle system to target activated microglia\/macrophages in spinal cord injury. Journal of Controlled Release, 174, 15\u201326.","journal-title":"Journal of Controlled Release"},{"key":"1301_CR92","doi-asserted-by":"publisher","first-page":"65","DOI":"10.14723\/tmrsj.37.65","volume":"37","author":"S Sato","year":"2012","unstructured":"Sato, S., Hiruma, Y., Nagata, H., & Takenaka, T. (2012). Excess potassium and microstructure control for producing dense KNbO3 ceramics. Transactions of Materials Research Society of Japan, 37, 65\u201368.","journal-title":"Transactions of Materials Research Society of Japan"},{"key":"1301_CR93","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1373\/clinchem.2007.090795","volume":"53","author":"KK Jain","year":"2007","unstructured":"Jain, K. K. (2007). Applications of nanobiotechnology in clinical diagnostics. Clinical Chemistry, 53, 2002\u20132009.","journal-title":"Clinical Chemistry"},{"key":"1301_CR94","doi-asserted-by":"publisher","first-page":"597","DOI":"10.2217\/nnm.10.35","volume":"5","author":"X Dong","year":"2010","unstructured":"Dong, X., & Mumper, R. J. (2010). Nanomedicinal strategies to treat multidrug-resistant tumors: Current progress. Nanomedicine, 5, 597\u2013615.","journal-title":"Nanomedicine"},{"key":"1301_CR95","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.ccr.2005.02.007","volume":"7","author":"R Satchi-Fainaro","year":"2005","unstructured":"Satchi-Fainaro, R., Mamluk, R., Wang, L., Short, S. M., Nagy, J. A., Feng, D., Dvorak, A. M., Dvorak, H. F., Puder, M., Mukhopadhyay, D., & Folkman, J. (2005). Inhibition of vessel permeability by TNP-470 and its polymer conjugate, caplostatin. Cancer Cell, 7, 251\u2013261.","journal-title":"Cancer Cell"},{"key":"1301_CR96","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nature03794","volume":"436","author":"S Sengupta","year":"2005","unstructured":"Sengupta, S., Eavarone, D., Capila, I., Zhao, G., Watson, N., Kiziltepe, T., & Sasisekharan, R. (2005). Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system. Nature, 436, 568\u2013572.","journal-title":"Nature"},{"key":"1301_CR97","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1021\/nn901465h","volume":"4","author":"P Chaudhuri","year":"2010","unstructured":"Chaudhuri, P., Harfouche, R., Soni, S., Hentschel, D. M., & Sengupta, S. (2010). Shape effect of carbon nanovectors on angiogenesis. ACS Nano, 4, 574\u2013582.","journal-title":"ACS Nano"},{"key":"1301_CR98","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.addr.2010.03.003","volume":"62","author":"JH Lee","year":"2010","unstructured":"Lee, J. H., Yigit, M. V., Mazumdar, D., & Lu, Y. (2010). Molecular diagnostic and drug delivery agents based on aptamer-nanomaterial conjugates. Advanced Drug Delivery Reviews, 62, 592\u2013605.","journal-title":"Advanced Drug Delivery Reviews"},{"key":"1301_CR99","doi-asserted-by":"publisher","first-page":"9965","DOI":"10.1021\/acsami.5b02276","volume":"7","author":"X Wu","year":"2015","unstructured":"Wu, X., Luo, L., Yang, S., Ma, X., Li, Y., Dong, C., Tian, Y., Zhang, L. E., Shen, Z., & Wu, A. (2015). Improved SERS nanoparticles for direct detection of circulating tumor cells in the blood. ACS Applied Materials & Interfaces, 7, 9965\u20139971.","journal-title":"ACS Applied Materials & Interfaces"},{"key":"1301_CR100","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1517\/17425240902932908","volume":"6","author":"ME Gindy","year":"2009","unstructured":"Gindy, M. E., & Prud\u2019homme, R. K. (2009). Multifunctional nanoparticles for imaging, delivery and targeting in cancer therapy. Expert Opinion on Drug Delivery, 6, 865\u2013878.","journal-title":"Expert Opinion on Drug Delivery"},{"key":"1301_CR101","first-page":"4062","volume":"63","author":"AM Mansour","year":"2003","unstructured":"Mansour, A. M., Drevs, J., Esser, N., Hamada, F. M., Badary, O. A., Unger, C., Fichtner, I., & Kratz, F. (2003). A new approach for the treatment of malignant melanoma: Enhanced antitumor efficacy of an albumin-binding doxorubicin prodrug that is cleaved by matrix metalloproteinase 2. Cancer Research, 63, 4062\u20134066.","journal-title":"Cancer Research"},{"key":"1301_CR102","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.ijpharm.2008.09.016","volume":"366","author":"A Garg","year":"2009","unstructured":"Garg, A., Tisdale, A. W., Haidari, E., & Kokkoli, E. (2009). Targeting colon cancer cells using PEGylated liposomes modified with a fibronectin-mimetic peptide. International Journal of Pharmaceutics, 366, 201\u2013210.","journal-title":"International Journal of Pharmaceutics"},{"key":"1301_CR103","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1002\/jps.20780","volume":"96","author":"PP Constantinides","year":"2007","unstructured":"Constantinides, P. P., & Wasan, K. M. (2007). Lipid formulation strategies for enhancing intestinal transport and absorption of P-glycoprotein (P-gp) substrate drugs: In vitro\/in vivo case studies. Journal of Pharmaceutical Science, 96, 235\u2013248.","journal-title":"Journal of Pharmaceutical Science"},{"key":"1301_CR104","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1023\/A:1015000503629","volume":"16","author":"JM Dintaman","year":"1999","unstructured":"Dintaman, J. M., & Silverman, J. A. (1999). Inhibition of P-glycoprotein by D-\u03b1-tocopheryl polyethylene glycol 1000 succinate (TPGS). Pharmaceutical Research, 16, 1550\u20131556.","journal-title":"Pharmaceutical Research"},{"key":"1301_CR105","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/978-3-642-00477-3_2","volume-title":"Drug Delivery, vol 197: Handbook of Experimental Pharmacology","author":"F Alexis","year":"2010","unstructured":"Alexis, F., Pridgen, E. M., Langer, R., & Farokhzad, O. C. (2010). Nanoparticle technologies for cancer therapy. In M. Sch\u00e4fer-Korting (Ed.), Drug Delivery, vol 197: Handbook of Experimental Pharmacology (pp. 55\u201386). Springer."},{"key":"1301_CR106","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.chembiol.2004.10.016","volume":"12","author":"Y Choi","year":"2005","unstructured":"Choi, Y., Thomas, T., Kotlyar, A., Islam, M. T., & Baker, J. R. (2005). Synthesis and functional evaluation of DNA-assembled polyamidoamine dendrimer clusters for cancer cell-specific targeting. Chemistry & Biology, 12, 35\u201343.","journal-title":"Chemistry & Biology"},{"key":"1301_CR107","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1586\/14737140.7.6.833","volume":"7","author":"MD Wang","year":"2007","unstructured":"Wang, M. D., Shin, D. M., Simons, J. W., & Nie, S. (2007). Nanotechnology for targeted cancer therapy. Expert Review of Anticancer Therapy, 7, 833\u2013837.","journal-title":"Expert Review of Anticancer Therapy"},{"key":"1301_CR108","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.2214\/ajr.172.5.10227514","volume":"172","author":"MG Harisinghani","year":"1999","unstructured":"Harisinghani, M. G., Saini, S., Weissleder, R., Hahn, P. F., Yantiss, R. K., Tempany, C., Wood, B. J., & Mueller, P. R. (1999). MR lymphangiography using ultrasmall superparamagnetic iron oxide in patients with primary abdominal and pelvic malignancies: Radiographic-pathologic correlation. AJR. American Journal of Roentgenology, 172, 1347\u20131351.","journal-title":"AJR. American Journal of Roentgenology"},{"key":"1301_CR109","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2014.00215","volume":"5","author":"G Tsivgoulis","year":"2014","unstructured":"Tsivgoulis, G., Katsanos, A. H., & Alexandrov, A. V. (2014). Reperfusion therapies of acute ischemic stroke: Potentials and failures. Frontiers in Neurology, 5, 113415.","journal-title":"Frontiers in Neurology"},{"key":"1301_CR110","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s10010-012-0153-z","volume":"76","author":"Y Lv","year":"2012","unstructured":"Lv, Y., Zou, Y., & Yang, L. (2012). Uncertainty and sensitivity analysis of properties of phase change micro\/nanoparticles for thermal protection during cryosurgery. Forschung im Ingenieurwesen, 76, 41\u201350.","journal-title":"Forschung im Ingenieurwesen"},{"key":"1301_CR111","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1093\/toxsci\/kfj122","volume":"91","author":"JP Ryman-Rasmussen","year":"2006","unstructured":"Ryman-Rasmussen, J. P., Riviere, J. E., & Monteiro-Riviere, N. A. (2006). Penetration of intact skin by quantum dots with diverse physicochemical properties. Toxicological Sciences, 91, 159\u2013165.","journal-title":"Toxicological Sciences"},{"key":"1301_CR112","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.biomaterials.2018.06.029","volume":"178","author":"G Jia","year":"2018","unstructured":"Jia, G., Han, Y., An, Y., Ding, Y., He, C., Wang, X., & Tang, Q. (2018). NRP-1 targeted and cargo-loaded exosomes facilitate simultaneous imaging and therapy of glioma in vitro and in vivo. Biomaterials, 178, 302\u2013316.","journal-title":"Biomaterials"},{"key":"1301_CR113","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s11051-008-9446-4","volume":"11","author":"J Jiang","year":"2009","unstructured":"Jiang, J., Oberd\u00f6rster, G., & Biswas, P. (2009). Characterization of size, surface charge, and agglomeration state of nanoparticle dispersions for toxicological studies. Journal of Nanoparticle Research, 11, 77\u201389.","journal-title":"Journal of Nanoparticle Research"},{"key":"1301_CR114","doi-asserted-by":"publisher","first-page":"78","DOI":"10.2174\/2468187306666160808160330","volume":"6","author":"R Awasthi","year":"2016","unstructured":"Awasthi, R., Pant, I., Kulkarni, T., G., Satiko Kikuchi, I., de Jesus Andreoli Pinto, T., Dua, K., Ramana Malipeddi, V. (2016). Opportunities and challenges in nano-structure mediated drug delivery: Where do we stand? Current Nanomedicine, 6, 78\u2013104.","journal-title":"Current Nanomedicine"},{"key":"1301_CR115","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1021\/nl061025k","volume":"6","author":"T Xia","year":"2006","unstructured":"Xia, T., Kovochich, M., Brant, J., Hotze, M., Sempf, J., Oberley, T., Sioutas, C., Yeh, J. I., Wiesner, M. R., & Nel, A. E. (2006). Comparison of the abilities of ambient and manufactured nanoparticles to induce cellular toxicity according to an oxidative stress paradigm. Nano Letters, 6, 1794\u20131807.","journal-title":"Nano Letters"},{"key":"1301_CR116","doi-asserted-by":"publisher","first-page":"20200190","DOI":"10.1002\/VIW.20200190","volume":"2","author":"X Liu","year":"2021","unstructured":"Liu, X., & Meng, H. (2021). Consideration for the scale-up manufacture of nanotherapeutics-A critical step for technology transfer. View, 2, 20200190.","journal-title":"View"},{"key":"1301_CR117","first-page":"1527","volume":"15","author":"R Paliwal","year":"2014","unstructured":"Paliwal, R., Babu, R. J., & Palakurthi, S. (2014). Nanomedicine scale-up technologies: Feasibilities and challenges. An Official Journal of the American Association of Pharmaceutical Scientists, 15, 1527\u20131534.","journal-title":"An Official Journal of the American Association of Pharmaceutical Scientists"},{"key":"1301_CR118","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1073\/pnas.0910603106","volume":"107","author":"KT Love","year":"2010","unstructured":"Love, K. T., Mahon, K. P., Levins, C. G., Whitehead, K. A., Querbes, W., Dorkin, J. R., Qin, J., Cantley, W., Qin, L. L., Racie, T., & Frank-Kamenetsky, M. (2010). Lipid-like materials for low-dose, in vivo gene silencing. Proceedings of the National Academy of Sciences, 107, 1864\u20131869.","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"1301_CR119","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/520609a","volume":"520","author":"NJ Schork","year":"2015","unstructured":"Schork, N. J. (2015). Personalized medicine: Time for one-person trials. Nature, 520, 609\u2013611.","journal-title":"Nature"},{"key":"1301_CR120","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1093\/bfgp\/elw025","volume":"16","author":"L Lu Xiao-Jie","year":"2017","unstructured":"Lu Xiao-Jie, L., Li-Juan, J., Torres-Ruiz, R., & Rodriguez-Perales, S. (2017). CRISPR-Cas9 technology: Applications and human disease modelling, brief.  Functional Genomics, 16, 4\u201312.","journal-title":"Functional Genomics"},{"key":"1301_CR121","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.699597","volume":"9","author":"SA Abdelnour","year":"2021","unstructured":"Abdelnour, S. A., Xie, L., Hassanin, A. A., Zuo, E., & Lu, Y. (2021). The potential of CRISPR\/Cas9 gene editing as a treatment strategy for inherited diseases. Frontiers of Cell and Developmental Biology, 9, 699597.","journal-title":"Frontiers of Cell and Developmental Biology"},{"key":"1301_CR122","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1126\/science.1225829","volume":"337","author":"M Jinek","year":"2012","unstructured":"Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012). A programmable dual-RNA\u2013guided DNA endonuclease in adaptive bacterial immunity. Science, 337, 816\u2013821.","journal-title":"Science"},{"key":"1301_CR123","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s00122-021-03984-y","volume":"135","author":"A Chaudhuri","year":"2022","unstructured":"Chaudhuri, A., Halder, K., & Datta, A. (2022). Classification of CRISPR\/Cas system and its application in tomato breeding. TAG. Theoretical and Applied Genetics., 135, 367\u2013387.","journal-title":"TAG. Theoretical and Applied Genetics."},{"key":"1301_CR124","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1093\/pcmedi\/pbab014","volume":"4","author":"W Liu","year":"2021","unstructured":"Liu, W., Li, L., Jiang, J., Wu, M., & Lin, P. (2021). Applications and challenges of CRISPR-Cas gene-editing to disease treatment in clinics. Precision Clinical Medicine, 4, 179\u2013191.","journal-title":"Precision Clinical Medicine"},{"key":"1301_CR125","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/s41392-023-01309-7","volume":"8","author":"T Li","year":"2023","unstructured":"Li, T., Yang, Y., Qi, H., Cui, W., Zhang, L., Fu, X., He, X., Liu, M., Li, P. F., & Yu, T. (2023). CRISPR\/Cas9 therapeutics: Progress and prospects. Signal Transduction and Targeted Therapy, 8, 36.","journal-title":"Signal Transduction and Targeted Therapy"},{"key":"1301_CR126","doi-asserted-by":"publisher","first-page":"9604","DOI":"10.3390\/ijms21249604","volume":"21","author":"E Janik","year":"2020","unstructured":"Janik, E., Niemcewicz, M., Ceremuga, M., Krzowski, L., Saluk-Bijak, J., & Bijak, M. (2020). Various aspects of a gene editing system\u2014crispr\u2013cas9. International Journal of Molecular Sciences, 21, 9604.","journal-title":"International Journal of Molecular Sciences"},{"key":"1301_CR127","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-021-01431-6","volume":"20","author":"H Zhang","year":"2021","unstructured":"Zhang, H., Qin, C., An, C., Zheng, X., Wen, S., Chen, W., Liu, X., Lv, Z., Yang, P., Xu, W., & Gao, W. (2021). Application of the CRISPR\/Cas9-based gene editing technique in basic research, diagnosis, and therapy of cancer. Molecular Cancer, 20, 1\u201322.","journal-title":"Molecular Cancer"},{"key":"1301_CR128","doi-asserted-by":"crossref","unstructured":"Asmamaw, M., & Zawdie, B. (2021) Mechanism and applications of CRISPR\/Cas-9-mediated genome editing. Biologics: Targets and Therapy, 15, 353\u2013361.","DOI":"10.2147\/BTT.S326422"},{"key":"1301_CR129","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/j.cell.2015.09.038","volume":"163","author":"B Zetsche","year":"2015","unstructured":"Zetsche, B., Gootenberg, J. S., Abudayyeh, O. O., Slaymaker, I. M., Makarova, K. S., Essletzbichler, P., Volz, S. E., Joung, J., Van Der Oost, J., Regev, A., & Koonin, E. V. (2015). Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system. Cell, 163, 759\u2013771.","journal-title":"Cell"},{"key":"1301_CR130","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1038\/s41587-020-0513-4","volume":"38","author":"JP Broughton","year":"2020","unstructured":"Broughton, J. P., Deng, X., Yu, G., Fasching, C. L., Servellita, V., Singh, J., Miao, X., Streithorst, J. A., Granados, A., Sotomayor-Gonzalez, A., & Zorn, K. (2020). CRISPR\u2013Cas12-based detection of SARS-CoV-2. Nature Biotechnology, 38, 870\u2013874.","journal-title":"Nature Biotechnology"},{"key":"1301_CR131","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s41664-022-00212-4","volume":"6","author":"M Qiu","year":"2022","unstructured":"Qiu, M., Zhou, X. M., & Liu, L. (2022). Improved strategies for CRISPR-Cas12-based nucleic acids detection. Journal of Analysis Test, 6, 44\u201352.","journal-title":"Journal of Analysis Test"},{"key":"1301_CR132","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1038\/nature24049","volume":"550","author":"OO Abudayyeh","year":"2017","unstructured":"Abudayyeh, O. O., Gootenberg, J. S., Essletzbichler, P., Han, S., Joung, J., Belanto, J. J., Verdine, V., Cox, D. B., Kellner, M. J., Regev, A., & Lander, E. S. (2017). RNA targeting with CRISPR\u2013Cas13. Nature, 550, 280\u2013284.","journal-title":"Nature"},{"key":"1301_CR133","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.jmb.2018.06.029","volume":"431","author":"MR O'Connell","year":"2019","unstructured":"O\u2019Connell, M. R. (2019). Molecular mechanisms of RNA targeting by Cas13-containing type VI CRISPR\u2013Cas systems. Journal of Molecular Biology, 431, 66\u201387.","journal-title":"Journal of Molecular Biology"},{"key":"1301_CR134","doi-asserted-by":"publisher","first-page":"1011399","DOI":"10.3389\/fmicb.2022.1011399","volume":"13","author":"Z Huang","year":"2022","unstructured":"Huang, Z., Fang, J., Zhou, M., Gong, Z., & Xiang, T. (2022). CRISPR-Cas13: A new technology for the rapid detection of pathogenic microorganisms. Frontiers in Microbiology, 13, 1011399.","journal-title":"Frontiers in Microbiology"},{"key":"1301_CR135","doi-asserted-by":"publisher","first-page":"4640","DOI":"10.3390\/cancers13184640","volume":"13","author":"B Dur\u00e1n-Vinet","year":"2021","unstructured":"Dur\u00e1n-Vinet, B., Araya-Castro, K., Calder\u00f3n, J., Vergara, L., Weber, H., Retamales, J., Araya-Castro, P., & Leal-Rojas, P. (2021). CRISPR\/Cas13-based platforms for a potential next-generation diagnosis of colorectal cancer through exosomes micro-RNA detection: A review. Cancers, 13, 4640.","journal-title":"Cancers"},{"key":"1301_CR136","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.jconrel.2022.01.013","volume":"342","author":"EA Taha","year":"2022","unstructured":"Taha, E. A., Lee, J., & Hotta, A. (2022). Delivery of CRISPR-Cas tools for in vivo genome editing therapy: Trends and challenges. Journal of Controlled Release, 342, 345\u2013361.","journal-title":"Journal of Controlled Release"},{"key":"1301_CR137","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1007\/s13346-023-01320-z","volume":"13","author":"F Sinclair","year":"2023","unstructured":"Sinclair, F., Begum, A. A., Dai, C. C., Toth, I., & Moyle, P. M. (2023). Recent advances in the delivery and applications of nonviral CRISPR\/Cas9 gene editing. Drug Delivery and Translational Research, 13, 1500\u20131519.","journal-title":"Drug Delivery and Translational Research"},{"key":"1301_CR138","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2022.942325","volume":"10","author":"J Huang","year":"2022","unstructured":"Huang, J., Zhou, Y., Li, J., Lu, A., & Liang, C. (2022). CRISPR\/Cas systems: Delivery and application in gene therapy. Frontiers of Bioengineering and Biotechnology, 10, 942325.","journal-title":"Frontiers of Bioengineering and Biotechnology"},{"key":"1301_CR139","doi-asserted-by":"publisher","first-page":"7353","DOI":"10.3390\/ijms21197353","volume":"21","author":"K Shalaby","year":"2020","unstructured":"Shalaby, K., Aouida, M., & El-Agnaf, O. (2020). Tissue-specific delivery of CRISPR therapeutics: Strategies and mechanisms of non-viral vectors. International Journal of Molecular Sciences, 21, 7353.","journal-title":"International Journal of Molecular Sciences"},{"key":"1301_CR140","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.3390\/ijms23031832","volume":"23","author":"E Erkut","year":"2022","unstructured":"Erkut, E., & Yokota, T. (2022). CRISPR therapeutics for Duchenne muscular dystrophy. International Journal of Molecular Sciences, 23, 1832.","journal-title":"International Journal of Molecular Sciences"},{"key":"1301_CR141","doi-asserted-by":"crossref","unstructured":"Xiang, X., Zhao, X., Pan, X., Dong, Z., Yu, J., Li, S., Liang, X., Han, P., Qu, K., Jensen, J.B., Farup, J. (2021). Efficient correction of Duchenne muscular dystrophy mutations by SpCas9 and dual gRNAs.\u00a0Molecular Theraphy-Nucleic Acids,\u00a024, 403\u2013415.","DOI":"10.1016\/j.omtn.2021.03.005"},{"key":"1301_CR142","doi-asserted-by":"crossref","unstructured":"Min, Y.L., Li, H., Rodriguez-Caycedo, C., Mireault, A.A., Huang, J., Shelton, J.M., McAnally, J.R., Amoasii, L., Mammen, P.P., Bassel-Duby, R., Olson, E.N. (2019). CRISPR-Cas9 corrects Duchenne muscular dystrophy exon 44 deletion mutations in mice and human cells.\u00a0Science Advances,\u00a05, eaav4324.","DOI":"10.1126\/sciadv.aav4324"},{"key":"1301_CR143","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1007\/s13311-022-01197-9","volume":"19","author":"CH Mbakam","year":"2022","unstructured":"Mbakam, C. H., Lamothe, G., Tremblay, G., & Tremblay, J. P. (2022). CRISPR-Cas9 gene therapy for Duchenne muscular dystrophy. Neurotherapy, 19, 931\u2013941.","journal-title":"Neurotherapy"},{"key":"1301_CR144","first-page":"567","volume":"22","author":"JN Nojadeh","year":"2023","unstructured":"Nojadeh, J. N., Eryilmaz, N. S. B., & Erg\u00fcder, B. \u0130. (2023). CRISPR\/Cas9 genome editing for neurodegenerative diseases. EXCLI Journal, 22, 567.","journal-title":"EXCLI Journal"},{"key":"1301_CR145","doi-asserted-by":"crossref","unstructured":"Konstantinidis, E., Molisak, A., Perrin, F., Streubel-Gallasch, L., Fayad, S., Kim, D.Y., Petri, K., Aryee, M.J., Aguilar, X., Gy\u00f6rgy, B., Giedraitis, V. (2022). CRISPR-Cas9 treatment partially restores amyloid-\u03b2 42\/40 in human fibroblasts with the Alzheimer\u2019s disease PSEN1 M146L mutation.\u00a0Molecular Theraohy-Nucleic Acids,\u00a028, 450\u2013461.","DOI":"10.1016\/j.omtn.2022.03.022"},{"key":"1301_CR146","doi-asserted-by":"publisher","first-page":"E476","DOI":"10.1073\/pnas.1618657114","volume":"114","author":"L Sun","year":"2017","unstructured":"Sun, L., Zhou, R., Yang, G., & Shi, Y. (2017). Analysis of 138 pathogenic mutations in presenilin-1 on the in vitro production of A\u03b242 and A\u03b240 peptides by \u03b3-secretase. Proceedings of the National Academy of Sciences, 114, E476\u2013E485.","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"1301_CR147","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/j.neuron.2018.05.008","volume":"98","author":"YT Lin","year":"2018","unstructured":"Lin, Y. T., Seo, J., Gao, F., Feldman, H. M., Wen, H. L., Penney, J., Cam, H. P., Gjoneska, E., Raja, W. K., Cheng, J., & Rueda, R. (2018). APOE4 causes widespread molecular and cellular alterations associated with Alzheimer\u2019s disease phenotypes in human iPSC-derived brain cell types. Neuron, 98, 1141\u20131154.","journal-title":"Neuron"},{"key":"1301_CR148","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.1016\/j.ymthe.2018.08.019","volume":"26","author":"B Kantor","year":"2018","unstructured":"Kantor, B., Tagliafierro, L., Gu, J., Zamora, M. E., Ilich, E., Grenier, C., Huang, Z. Y., Murphy, S., & Chiba-Falek, O. (2018). Downregulation of SNCA expression by targeted editing of DNA methylation: A potential strategy for precision therapy in PD. Molecular Therapy, 26, 2638\u20132649.","journal-title":"Molecular Therapy"},{"key":"1301_CR149","doi-asserted-by":"publisher","first-page":"3107","DOI":"10.1093\/hmg\/ddaa183","volume":"29","author":"V Chen","year":"2020","unstructured":"Chen, V., Moncalvo, M., Tringali, D., Tagliafierro, L., Shriskanda, A., Ilich, E., Dong, W., Kantor, B., & Chiba-Falek, O. (2020). The mechanistic role of alpha-synuclein in the nucleus: Impaired nuclear function caused by familial Parkinson\u2019s disease SNCA mutations. Human Molecular Genetics, 29, 3107\u20133121.","journal-title":"Human Molecular Genetics"},{"key":"1301_CR150","doi-asserted-by":"crossref","unstructured":"Wulansari, N., Darsono, W.H.W., Woo, H.J., Chang, M.Y., Kim, J., Bae, E.J., Sun, W., Lee, J.H., Cho, I.J., Shin, H., Lee, S.J. (2021). Neurodevelopmental defects and neurodegenerative phenotypes in human brain organoids carrying Parkinson\u2019s disease-linked DNAJC6 mutations.\u00a0Science Advance,\u00a07, eabb1540.","DOI":"10.1126\/sciadv.abb1540"},{"key":"1301_CR151","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.cell.2018.03.005","volume":"173","author":"S Yan","year":"2018","unstructured":"Yan, S., Tu, Z., Liu, Z., Fan, N., Yang, H., Yang, S., Yang, W., Zhao, Y., Ouyang, Z., Lai, C., & Yang, H. (2018). A huntingtin knockin pig model recapitulates features of selective neurodegeneration in Huntington\u2019s disease. Cell, 173, 989\u20131002.","journal-title":"Cell"},{"issue":"1","key":"1301_CR152","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1038\/s42003-023-04829-8","volume":"6","author":"JH Seo","year":"2023","unstructured":"Seo, J. H., Shin, J. H., Lee, J., Kim, D., Hwang, H. Y., Nam, B. G., Lee, J., Kim, H. H., & Cho, S. R. (2023). DNA double-strand break-free CRISPR interference delays Huntington\u2019s disease progression in mice. CCommunications Biology, 6(1), 466.","journal-title":"Communications Biology"},{"key":"1301_CR153","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s12943-022-01559-z","volume":"21","author":"A Dimitri","year":"2022","unstructured":"Dimitri, A., Herbst, F., & Fraietta, J. A. (2022). Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing. Molecular Cancer, 21, 78.","journal-title":"Molecular Cancer"},{"key":"1301_CR154","doi-asserted-by":"publisher","first-page":"4902","DOI":"10.1073\/pnas.1920478117","volume":"117","author":"M Warner","year":"2020","unstructured":"Warner, M., Wu, W. F., Montanholi, L., Nalvarte, I., Antonson, P., & Gustafsson, J. A. (2020). Ventral prostate and mammary gland phenotype in mice with complete deletion of the ER\u03b2 gene. Proceedings of the National Academy of Sciences, 117, 4902\u20134909.","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"1301_CR155","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/s41586-022-05531-1","volume":"615","author":"SP Foy","year":"2023","unstructured":"Foy, S. P., Jacoby, K., Bota, D. A., Hunter, T., Pan, Z., Stawiski, E., Ma, Y., Lu, W., Peng, S., Wang, C. L., & Yuen, B. (2023). Non-viral precision T cell receptor replacement for personalized cell therapy. Nature, 615, 687\u2013696.","journal-title":"Nature"},{"key":"1301_CR156","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.3390\/cancers15061813","volume":"15","author":"D Stefanoudakis","year":"2023","unstructured":"Stefanoudakis, D., Kathuria-Prakash, N., Sun, A. W., Abel, M., Drolen, C. E., Ashbaugh, C., Zhang, S., Hui, G., Tabatabaei, Y. A., Zektser, Y., & Lopez, L. P. (2023). The potential revolution of cancer treatment with CRISPR technology. Cancers, 15, 1813.","journal-title":"Cancers"},{"key":"1301_CR157","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s40265-015-0522-7","volume":"76","author":"SL Greig","year":"2016","unstructured":"Greig, S. L. (2016). Talimogene laherparepvec: First global approval. Drugs, 76, 147\u2013154.","journal-title":"Drugs"},{"key":"1301_CR158","doi-asserted-by":"publisher","first-page":"737","DOI":"10.15252\/emmm.201707573","volume":"9","author":"A Aiuti","year":"2017","unstructured":"Aiuti, A., Roncarolo, M. G., & Naldini, L. (2017). Gene therapy for ADA-SCID, the first marketing approval of an ex vivo gene therapy in Europe: Paving the road for the next generation of advanced therapy medicinal products. EMBO Molecular Medicine, 9, 737\u2013740.","journal-title":"EMBO Molecular Medicine"},{"key":"1301_CR159","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1007\/s40265-016-0657-1","volume":"76","author":"YY Syed","year":"2016","unstructured":"Syed, Y. Y. (2016). Eteplirsen: First global approval. Drugs, 76, 1699\u20131704.","journal-title":"Drugs"},{"key":"1301_CR160","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1358\/dot.2017.53.11.2725754","volume":"53","author":"Y Liu","year":"2017","unstructured":"Liu, Y., Chen, X., Han, W., & Zhang, Y. (2017). Tisagenlecleucel, an approved anti-CD19 chimeric antigen receptor T-cell therapy for the treatment of leukemia. Drugs of Today (Barcelona, Spain), 53, 597\u2013608.","journal-title":"Drugs of Today (Barcelona, Spain)"},{"key":"1301_CR161","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1007\/s40265-019-01162-5","volume":"79","author":"SM Hoy","year":"2019","unstructured":"Hoy, S. M. (2019). Onasemnogene abeparvovec: First global approval. Drugs, 79, 1255\u20131262.","journal-title":"Drugs"},{"key":"1301_CR162","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s40265-020-01267-2","volume":"80","author":"YA Heo","year":"2020","unstructured":"Heo, Y. A. (2020). Golodirsen: First approval. Drugs, 80, 329\u2013333.","journal-title":"Drugs"},{"key":"1301_CR163","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1007\/s40265-020-01339-3","volume":"80","author":"S Dhillon","year":"2020","unstructured":"Dhillon, S. (2020). Viltolarsen: First approval. Drugs, 80, 1027\u20131031.","journal-title":"Drugs"},{"key":"1301_CR164","unstructured":"Squibb, B.M. (2021). US Food and Drug Administration approves Bristol Myers Squibb\u2019s and bluebird bio\u2019s Abecma (idecabtagenevicleucel), the first anti-BCMA CAR T cell therapy for relapsed or refractory multiple myeloma; 2021 (updated 2021 Mar 26; 2021 May 14)."},{"key":"1301_CR165","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/s40265-021-01512-2","volume":"81","author":"M Shirley","year":"2021","unstructured":"Shirley, M. (2021). Casimersen: First approval. Drugs, 81, 875\u2013879.","journal-title":"Drugs"},{"key":"1301_CR166","doi-asserted-by":"crossref","unstructured":"Asghar, A.A., Khabir, Y., Hashmi, M.R. (2022) Zynteglo: Betibeglogene autotemcel\u2013An innovative therapy for \u03b2-thalassemia patients.\u00a0Annals of Medicine and Surgery,\u00a082.","DOI":"10.1016\/j.amsu.2022.104624"},{"key":"1301_CR167","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., & Timmerman, J. M. (2017). Axicabtageneciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. New England Journal of Medicine, 377, 2531\u20132544.","journal-title":"New England Journal of Medicine"},{"key":"1301_CR168","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1007\/s40265-022-01788-y","volume":"82","author":"HA Blair","year":"2022","unstructured":"Blair, H. A. (2022). Valoctocogene roxaparvovec: First approval. Drugs, 82, 1505\u20131510.","journal-title":"Drugs"},{"key":"1301_CR169","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1002\/ajh.26741","volume":"98","author":"J Kanter","year":"2023","unstructured":"Kanter, J., Thompson, A. A., Pierciey, F. J., Jr., Hsieh, M., Uchida, N., Leboulch, P., Schmidt, M., Bonner, M., Guo, R., Miller, A., & Ribeil, J. A. (2023). Lovo-cel gene therapy for sickle cell disease: Treatment process evolution and outcomes in the initial groups of the HGB-206 study. American Journal of Hematology, 98, 11\u201322.","journal-title":"American Journal of Hematology"},{"key":"1301_CR170","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1007\/s40265-023-01929-x","volume":"83","author":"SM Hoy","year":"2023","unstructured":"Hoy, S. M. (2023). Delandistrogene Moxeparvovec: First approval. Drugs, 83, 1323\u20131329.","journal-title":"Drugs"},{"key":"1301_CR171","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ymthe.2023.12.001","volume":"32","author":"R Han","year":"2024","unstructured":"Han, R. (2024). First in vivo base-editing trial shows promise. Molecular Therapy, 32, 1\u20132.","journal-title":"Molecular Therapy"},{"key":"1301_CR172","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s40265-023-01846-z","volume":"83","author":"A Lee","year":"2023","unstructured":"Lee, A. (2023). Nadofaragene firadenovec: First approval. Drugs, 83, 353\u2013357.","journal-title":"Drugs"},{"key":"1301_CR173","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s40265-024-02017-4","volume":"84","author":"S Dhillon","year":"2024","unstructured":"Dhillon, S. (2024). Fidanacogene Elaparvovec: First approval. Drugs, 84, 479\u2013486.","journal-title":"Drugs"},{"key":"1301_CR174","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/s41591-018-0326-x","volume":"25","author":"CT Charlesworth","year":"2019","unstructured":"Charlesworth, C. T., Deshpande, P. S., Dever, D. P., Camarena, J., Lemgart, V. T., Cromer, M. K., Vakulskas, C. A., Collingwood, M. A., Zhang, L., Bode, N. M., & Behlke, M. A. (2019). Identification of preexisting adaptive immunity to Cas9 proteins in humans. Nature Medicine, 25, 249\u2013254.","journal-title":"Nature Medicine"},{"key":"1301_CR175","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-021-01487-4","volume":"21","author":"MF Rasul","year":"2022","unstructured":"Rasul, M. F., Hussen, B. M., Salihi, A., Ismael, B. S., Jalal, P. J., Zanichelli, A., Jamali, E., Baniahmad, A., Ghafouri-Fard, S., Basiri, A., & Taheri, M. (2022). Strategies to overcome the main challenges of the use of CRISPR\/Cas9 as a replacement for cancer therapy. Molecular Cancer, 21, 1\u201330.","journal-title":"Molecular Cancer"},{"key":"1301_CR176","doi-asserted-by":"crossref","unstructured":"D\u2019Souza, R. F., Mathew, M., Surapaneni, K. M. (2023). A scoping review on the ethical issues in the use of CRISPR-Cas9 in the creation of human disease models.\u00a0Journal of Clinical and Diagnostic Research,\u00a017.","DOI":"10.7860\/JCDR\/2023\/68275.18809"},{"key":"1301_CR177","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1038\/s41591-018-0049-z","volume":"24","author":"E Haapaniemi","year":"2018","unstructured":"Haapaniemi, E., Botla, S., Persson, J., Schmierer, B., & Taipale, J. (2018). CRISPR\u2013Cas9 genome editing induces a p53-mediated DNA damage response. Nature Medicine, 24, 927\u2013930.","journal-title":"Nature Medicine"},{"key":"1301_CR178","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/nbt.4192","volume":"36","author":"M Kosicki","year":"2018","unstructured":"Kosicki, M., Tomberg, K., & Bradley, A. (2018). Repair of double-strand breaks induced by CRISPR\u2013Cas9 leads to large deletions and complex rearrangements. Nature Biotechnology, 36, 765\u2013771.","journal-title":"Nature Biotechnology"},{"key":"1301_CR179","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1038\/s41467-019-09006-2","volume":"10","author":"G Cullot","year":"2019","unstructured":"Cullot, G., Boutin, J., Toutain, J., Prat, F., Pennamen, P., Rooryck, C., Teichmann, M., Rousseau, E., Lamrissi-Garcia, I., Guyonnet-Duperat, V., & Bibeyran, A. (2019). CRISPR-Cas9 genome editing induces megabase-scale chromosomal truncations. Nature Communications, 10, 1136.","journal-title":"Nature Communications"},{"key":"1301_CR180","doi-asserted-by":"crossref","unstructured":"Moses, C., Nugent, F., Waryah, C. B., Garcia-Bloj, B., Harvey, A. R., Blancafort, P. (2019). Activating PTEN tumor suppressor expression with the CRISPR\/dCas9 system.\u00a0Molecular Theraphy-Nucleic Acids\u00a014, 287\u2013300","DOI":"10.1016\/j.omtn.2018.12.003"},{"key":"1301_CR181","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/s41551-019-0431-2","volume":"3","author":"AM Moreno","year":"2019","unstructured":"Moreno, A. M., Palmer, N., Alem\u00e1n, F., Chen, G., Pla, A., Jiang, N., Leong Chew, W., Law, M., & Mali, P. (2019). Immune-orthogonal orthologues of AAV capsids and of Cas9 circumvent the immune response to the administration of gene therapy. Nature Biomedical Engineering, 3, 806\u2013816.","journal-title":"Nature Biomedical Engineering"},{"key":"1301_CR182","doi-asserted-by":"publisher","first-page":"874","DOI":"10.2105\/AJPH.2023.307315","volume":"113","author":"AM Subica","year":"2023","unstructured":"Subica, A. M. (2023). CRISPR in public health: The health equity implications and role of community in gene-editing research and applications. American Journal of Public Health, 113, 874\u2013882.","journal-title":"American Journal of Public Health"},{"key":"1301_CR183","doi-asserted-by":"crossref","unstructured":"Ackerman, C. M., Myhrvold, C., Thakku, S. G., Freije, C. A., Metsky, H. C., Yang, D. K., Ye, S. H., Boehm, C. K., Kosoko-Thoroddsen, T. S. F., Kehe, J., & Nguyen, T. G. (2020). Massively multiplexed nucleic acid detection with Cas13. Nature, 582, 277\u2013282.","DOI":"10.1038\/s41586-020-2279-8"},{"key":"1301_CR184","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1089\/crispr.2017.0024","volume":"1","author":"C Brokowski","year":"2018","unstructured":"Brokowski, C. (2018). Do CRISPR germline ethics statements cut it? CRISPR Journal, 1, 115\u2013125.","journal-title":"CRISPR Journal"}],"container-title":["Molecular Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12033-024-01301-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12033-024-01301-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12033-024-01301-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T19:02:55Z","timestamp":1759258975000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12033-024-01301-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,24]]},"references-count":184,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["1301"],"URL":"https:\/\/doi.org\/10.1007\/s12033-024-01301-8","relation":{},"ISSN":["1073-6085","1559-0305"],"issn-type":[{"value":"1073-6085","type":"print"},{"value":"1559-0305","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,24]]},"assertion":[{"value":"25 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"On behalf of all authors, it is stated that there is no conflict of interest related to the present manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"It is stated that the present study does not involve any kind of human participants and\/or animals.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research Involving Human Participants\/Animals"}}]}}